News•Apr 9, 2026
Accelerating Into Fraud
MEDVi, a two‑person telehealth startup, is projected to generate $1.8 billion in 2026 by selling compounded GLP‑1 weight‑loss drugs through the white‑labeled OpenLoop platform. The company relies heavily on AI‑generated marketing, virtual doctors, and automated customer service to drive sales. A RICO lawsuit alleges MEDVi sold oral tirzepatide that functions no better than a placebo, while the FTC has sued the firm for undisclosed AI doctor ads and spam‑law violations. The case highlights how AI can be weaponized to scale fraudulent health‑care operations.
